8-K: Aptevo Therapeutics Updates At-The-Market Offering, Increasing Available Capital to Over $8 Million

Aptevo Therapeutics Inc. has filed a prospectus supplement to update its existing At The Market (ATM) offering program, allowing for the sale of up to an additional $8,037,381 in common stock.

Summary

• Aptevo Therapeutics Inc. filed a prospectus supplement on June 20, 2025, updating its At The Market (ATM) offering program.
• The updated program allows for the offer and sale of common stock with an aggregate offering price of up to $8,037,381.
• This supplement amends previous prospectus supplements filed on April 28, 2025, April 29, 2025, and May 22, 2025.
• As of June 20, 2025, the company had already issued and sold 481,828 shares of common stock under the Sales Agreement, generating aggregate gross sale proceeds of $3,765,143.
• The total registration statement on Form S-3 allows for the sale of up to $100,000,000 of various securities.

Sentiment

Score: 5

Explanation: The document is a procedural filing related to an At The Market (ATM) offering, which is a standard capital-raising mechanism. It does not contain specific positive or negative operational results or forward-looking statements that would significantly sway sentiment beyond the neutral act of facilitating future capital raises.

Positives

• Provides Aptevo Therapeutics with continued access to capital through an At The Market offering, allowing for flexible fundraising.
• The company has already successfully raised $3,765,143 through the sale of 481,828 shares under the existing Sales Agreement.

Negatives

• The ongoing At The Market offering could lead to dilution for existing shareholders as new shares are issued.

Risks

• Dilution Risk: The sale of additional common stock under the ATM program will increase the number of outstanding shares, potentially diluting the ownership interest of existing shareholders.
• Market Price Volatility: The actual proceeds from the ATM offering will depend on the market price of the common stock at the time of sale, which can fluctuate significantly.
• Uncertainty of Proceeds: There is no guarantee that the company will sell the full amount of shares authorized under the ATM program, or that it will do so at favorable prices.

Future Outlook

Aptevo Therapeutics intends to continue utilizing its At The Market offering program to raise capital by selling shares of common stock from time to time, up to the remaining authorized amount of $8,037,381.

Management Comments

• The report was signed by Marvin L. White, President and Chief Executive Officer of Aptevo Therapeutics Inc.

Industry Context

At The Market (ATM) offerings are a common and flexible financing tool for biotechnology and pharmaceutical companies like Aptevo Therapeutics, allowing them to raise capital incrementally to fund ongoing research and development, clinical trials, or general corporate purposes without the immediate pressure of a large, single offering. This method is particularly prevalent in industries with high capital expenditure requirements and uncertain timelines for product development.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for dilution of existing shareholdings as new common stock is issued and sold under the ATM program.
• Company Operations: Provides capital flexibility to fund ongoing operations, research and development, and other corporate purposes.

Next Steps

• Continued offer and sale of common stock under the At The Market offering program.

Key Dates

Keywords

Aptevo Therapeutics, ATM offering, common stock, capital raise, prospectus supplement, Form S-3, Roth Capital Partners, equity financing, dilution, biotechnology, pharmaceuticals